NUVL

Nuvalent Inc - Ordinary Shares - Class A

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) has received an average recommendation of "Moderate Buy" from the seventeen ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and sixteen have given a b...

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Deborah Ann Miller sold 5,500 shares of the company's stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $99.22, for a total value of $545,710.00. Following the completion of the sale, the...

(RTTNews) - Thursday, Guardant Health, Inc. (GH) announced a multi-year strategic collaboration with Nuvalent, Inc. (NUVL) to support the development and potential commercialization of the latter's...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical...

Pictet Asset Management Holding SA cut its stake in Nuvalent, Inc. (NASDAQ:NUVL - Free Report) by 7.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 355,681 shares of the company's stock after selling 2...

Nuvalent (NASDAQ:NUVL) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-nuvalent-inc-stock...

Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting Nuvalent to Present...

HC Wainwright reiterated a "buy" rating and set a $155.00 price target on shares of Nuvalent in a report on Tuesday...

New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 PR Newswire CAMBRIDGE, Mass., April 17, 2026 Zidesamtinib...